Volunteer with the British Society for Haematology
Learn more about how to become a volunteer with BSH and all the work our valuable volunteers create.
Related Articles
Pirtobrutinib Bests Investigators’ Choice After cBTKi Failure in CLL/SLL
Pirtobrutinib improved outcomes over investigator’s choice of treatment in patients with CLL/SLL previously treated with a cBTKi.
CARNIVORE Diet (Beginner’s Guide) All You Need to Get Started – 2023
Thousands of people, and many previous cultures, have used a Carnivore Diet to improve their health. This longer video lists everything you need to know…
Early Career Award | Cancer Discovery | American Association for Cancer Research
Early Career Award | Cancer Discovery | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none; } .right{float:…
Advances in liquid biopsy: From exploration to practical application
Liquid biopsy has received tremendous attention as a non-invasive approach for detecting and tracking cancer. Here, we discuss the latest work on circulating tumor DNA…
MCP 60 Seconds With Ross Arena, PhD, on Pharma-cise™
View Full-Length Video at: https://youtu.be/tFJeQ0mMeFERelated Article Available at: https://mayocl.in/3U7nRj8
Pembrolizumab Improves Upon THP in HER2+ Breast Cancer
Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.
FDA Greenlights Cosibelimab in Metastatic or Locally Advanced CSCC
Cosibelimab is now FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not eligible for curative…
Certain Breast Cancer Patients Can Safely Skip Chest Wall Irradiation, Data Suggest
Chest wall irradiation after mastectomy did not improve 10-year overall survival in patients with intermediate-risk breast cancer.
Home | ATTR Revealed
ATTR amyloidosis (ATTR) is a progressive disease, which means it can worsen over time. Early diagnosis is crucial, talk with your doctor today.
ctDNA: ZEST Trial Cleans Up Breast Cancer Treatment – Niraparib (ZEJULA) vs. Placebo in High-Risk TNBC and BRCA-Mutated Patients
Findings from the ZEST trial highlight the potential of ctDNA surveillance in breast cancer management. Discover the role of Niraparib in enhancing disease-free survival.
